Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
Innovation (Cambridge (Mass.))|January 3, 2022
Profiling of immune features to predict immunotherapy efficacyYouqiong Ye, Yongchang Zhang, Nong Yang, et al.
Genome Medicine|September 29, 2020
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1Youqiong Ye, Xinwei Kuang, Zuozhong Xie, et al.
Iscience|August 20, 2025
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLCLianxi Song, Liang Zeng, Qinqin Xu, et al.
Ebiomedicine|February 21, 2025
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental studyZhe Huang, Abdoulaye Karaboué, Liang Zeng, et al.
Nature|March 13, 2025
Spatial immune scoring system predicts hepatocellular carcinoma recurrenceGengjie Jia, Peiqi He, Tianli Dai, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2022
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangementsYuxiang Ma, Hongyun Zhao, Jinhui Xue, et al.
The Lancet Regional Health. Western Pacific|April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 25, 2024
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective studyZhe Huang, Yuda Zhang, Qinqin Xu, et al.
Med (New York, N.Y.)|February 1, 2025
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trialLiang Zeng, Huan Yan, Wenjuan Jiang, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2024
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in ChinaHuan Yan, Lianxi Song, Yizhi Li, et al.
Pageof 17